Advances in the study of the correlation between incretin hormone GIP and polycystic ovary syndrome

doi:10.11958/20240051

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is one of the most common reproductive and endocrine disorders in women of childbearing age, and the pathogenesis is unknown. Insulin resistance, hyperandrogenism and obesity are important pathophysiological basis. Glucose-dependent insulinotropic peptide (GIP) is a gastrointestinal hormone involved in the regulation of insulin secretion. Literature studies have shown that GIP is correlated with insulin resistance, hyperandrogenism, obesity and other characteristic changes of PCOS, and it may contribute to the onset and progression of PCOS by affecting the function of hypothalamic-pituitary-ovarian axis, suggesting that GIP is associated with PCOS. This paper reviews the research progress of the correlation between GIP and PCOS.

Key words: polycystic ovary syndrome, obesity, insulin resistance, glucose-dependent insulinotropic polypeptide, hyperandrogenism, hypothalamic-pituitary-ovarian axis

CLC Number:

R711.75，R588.6

References 40

[1]	ESCOBAR-MORREALE H F. Polycystic ovary syndrome:definition,aetiology,diagnosis and treatment[J]. Nat Rev Endocrinol, 2018, 14(5):270-284. doi:10.1038/nrendo.2018.24.
[2]	YU O, CHRIST J P, SCHULZE-RATH R, et al. Incidence,prevalence,and trends in polycystic ovary syndrome diagnosis:a United States population-based study from 2006 to 2019[J]. Am J Obstet Gynecol, 2023, 229(1):39.e1-39.e12. doi:10.1016/j.ajog.2023.04.010.
[3]	GABE M, SKOV-JEPPESEN K, GASBJERG L S, et al. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment[J]. Pharmacol Res, 2022,176:106058. doi:10.1016/j.phrs.2022.106058.
[4]	VASTO S, AMATO A, PROIA P, et al. Is the secret in the gut? SuperJump activity improves bone remodeling and glucose homeostasis by GLP-1 and GIP peptides in eumenorrheic women[J]. Biology (Basel), 2022, 11(2):296. doi:10.3390/biology11020296.
[5]	ZHANG Z Q, HÖLSCHER C. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models[J]. Peptides, 2020,125:170184. doi:10.1016/j.peptides.2019.170184.
[6]	AHRÉN B. Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion:the human literature revisited and a systematic study in model experiments in mice[J]. J Diabetes Investig, 2022, 13(10):1655-1665. doi:10.1111/jdi.13836.
[7]	HÖLSCHER C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models[J]. Neuropharmacology, 2018, 136(Pt B):251-259. doi:10.1016/j.neuropharm.2018.01.040.
[8]	REGAZZO D, BERTAZZA L, GALLETTA E, et al. The GIP/GIPR axis in medullary thyroid cancer:clinical and molecular findings[J]. Endocr Relat Cancer, 2022, 29(5):273-284. doi:10.1530/ERC-21-0258.
[9]	ROMITTI M, FABRIS V C, ZIEGELMANN P K, et al. Association between PCOS and autoimmune thyroid disease:a systematic review and meta-analysis[J]. Endocr Connect, 2018, 7(11):1158-1167. doi:10.1530/EC-18-0309.
[10]	SHEKHAWAT V S, BHANSALI S, DUTTA P, et al. Glucose-dependent insulinotropic polypeptide(GIP)resistance and β-cell dysfunction contribute to hyperglycaemia in acromegaly[J]. Sci Rep, 2019, 9(1):5646. doi:10.1038/s41598-019-41887-7.
[11]	HEIMBÜRGER S M, BERGMANN N C, AUGUSTIN R, et al. Glucose-dependent insulinotropic polypeptide(GIP)and cardiovascular disease[J]. Peptides, 2020, 125:170-174. doi:10.1016/j.peptides.2019.170174.
[12]	KHAN D, OJO O O, WOODWARD O R, et al. Evidence for involvement of GIP and GLP-1 receptors and the gut-gonadal axis in regulating female reproductive function in mice[J]. Biomolecules, 2022, 12(12):1736. doi:10.3390/biom12121736.
[13]	NISHIYAMA Y, HASEGAWA T, FUJITA S, et al. Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells[J]. J Steroid Biochem Mol Biol, 2018, 178:82-88. doi:10.1016/j.jsbmb.2017.11.004.
[14]	DHANKHAR S, CHAUHAN S, MEHTA D K, et al. Novel targets for potential therapeutic use in diabetes mellitus[J]. Diabetol Metab Syndr, 2023, 15(1):17. doi:10.1186/s13098-023-00983-5.
[15]	STEPTO N K, CASSAR S, JOHAM A E, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp[J]. Hum Reprod, 2013, 28(3):777-784. doi:10.1093/humrep/des463.
[16]	CENA H, CHIOVATO L, NAPPI R E. Obesity,polycystic ovary syndrome,and infertility:a new avenue for GLP-1 receptor agonists[J]. J Clin Endocrinol Metab, 2020, 105(8):e2695-2709. doi:10.1210/clinem/dgaa285.
[17]	THANNICKAL A, BRUTOCAO C, ALSAWAS M, et al. Eating,sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS):a systematic review and meta-analysis[J]. Clin Endocrinol(Oxf), 2020, 92(4):338-349. doi:10.1111/cen.14153.
[18]	WILLIAMS S, FIDO D, SHEFFIELD D. Polycystic ovary syndrome(PCOS)and non-suicidal self-injury(NSSI):a community-based study[J]. Healthcare (Basel), 2022, 10(6):1118. doi:10.3390/healthcare10061118.
[19]	袁莹莹, 赵君利. 多囊卵巢综合征流行病学特点[J]. 中国实用妇科与产科志, 2019, 35(3):261-264.
	YUAN Y Y, ZHAO J L. Epidemiological features of polycystic ovary syndrome[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2019, 35(3):261-264. doi:10.19538/j.fk2019030102.
[20]	马良坤. 多囊卵巢综合征的胰岛素增敏治疗[D]. 北京: 中国协和医科大学, 2008.
	MA L K. Insulin sensitizing treatment of polycystic ovarian syndrome[D]. Beijing: Peking Union Medical College, 2008.
[21]	McCLEAN P L, IRWIN N, CASSIDY R S, et al. GIP receptor antagonism reverses obesity,insulin resistance,and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet[J]. Am J Physiol Endocrinol Metab, 2007, 293(6):E1746-E1755. doi:10.1152/ajpendo.00460.2007.
[22]	CLEMENTS R H, GONZALEZ Q H, LONG C I, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus[J]. Am Surg. 2004, 70(1):1-5.
[23]	张宏伟. 腹腔镜胃旁路手术对肥胖型Ⅱ型糖尿病的临床研究[D]. 长春: 吉林大学, 2019.
	ZHANG H W. Clinical research of laparoscopic gastric bypass operation in promoting the type 2 diabetes mellitus[D]. Changchun: Jilin University, 2019.
[24]	LYU X, YAN K, HU W, et al. Safflower yellow and its main component hydroxysafflor yellow A alleviate hyperleptinemia in diet-induced obesity mice through a dual inhibition of the GIP-GIPR signaling axis[J]. Phytother Res,2023 March 21. doi:10.1002/ptr.7788. [Epub ahead of print].
[25]	徐丹凤, 谢华, 陈敏, 等. 亚麻籽油对肥胖2型糖尿病小鼠体质量、血糖、胃肠激素水平的影响[J]. 山东医药, 2019, 59(32):5-7.
	XU D F, XIE H, CHEN M, et al. Effects of linseed oil on body weight,blood glucose and gastrointestinal hormone secretion in obese type 2 diabetic mice[J]. Shandong Medical Journal, 2019, 59(32):5-7.
[26]	SVENDSEN P F, NILAS L, MADSBAD S, et al. Incretin hormone secretion in women with polycystic ovary syndrome:roles of obesity,insulin sensitivity,and treatment with metformin[J]. Metabolism, 2009, 58(5):586-593. doi:10.1016/j.metabol.2008.11.009.
[27]	李萍, 沙艳伟, 丁露, 等. PCOS患者肠促胰素水平变化及其在发病中的作用研究[J]. 中国妇幼保健, 2015, 30(31):5421-5423.
	LI P, SHA Y W, DING L, et al. Changes of incretin levels in PCOS patients and its role in pathogenesis of PCOS[J]. Maternal and Child Health Care of China, 2015, 30(31):5421-5423.
[28]	张红裔, 吕洪亮, 谷洋, 等. 非肥胖型2型糖尿病空肠回肠侧侧吻合术后血糖与GIP变化的相关性研究[J]. 中国实验诊断学, 2023, 27(7):821-824.
	ZHANG H Y, LYU H L, GU Y, et al. Correlation between blood glucose and GIP changes after lateral jejuno-ileal anastomosis in non-obese type 2 diabetes mellitus[J]. Chinese Journal of Laboratory Diagnosis, 2023, 27(7):821-824.
[29]	THOMAS M K, NIKOOIENEJAD A, BRAY R, et al. Dual GIP and GLP-1 receptor agonist Tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes[J]. J Clin Endocrinol Metab, 2021, 106(2):388-396. doi:10.1210/clinem/dgaa863.
[30]	DIAMANTI-KANDARAKIS E, DUNAIF A. Insulin resistance and the polycystic ovary syndrome revisited:an update on mechanisms and implications[J]. Endocr Rev, 2012, 33(6):981-1030. doi:10.1210/er.2011-1034.
[31]	徐晶, 申丽媛, 屈清华. 基于PI3K/AKT通路探究柚皮素改善多囊卵巢综合征大鼠胰岛素抵抗的作用机制[J]. 天津医药, 2022, 50(3):270-275.
	XU J, SHEN L Y, QU Q H. Study on the mechanism of naringenin improving insulin resistance in rats with polycystic ovary syndrome based on PI3K/AKT pathway[J]. Tianjin Med J, 2022, 50(3):270-275. doi:10.11958/20212367.
[32]	KIM S J, NIAN C, KARUNAKARAN S, et al. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis,and improved glucose homeostasis[J]. PLoS One, 2012, 7(7):e40156. doi:10.1371/journal.pone.0040156.
[33]	SVENDSEN P F, JENSEN F K, HOLST J J, et al. The effect of a very low calorie diet on insulin sensitivity,beta cell function,insulin clearance,incretin hormone secretion,androgen levels and body composition in obese young women[J]. Scand J Clin Lab Invest, 2012, 72(5):410-419. doi:10.3109/00365513.2012.691542.
[34]	MILEWICZ T, MIGACZ K, KIAłKA M, et al. Basic and meal stimulated plasma GIP levels are higher in lean PCOS women with FAI over 5[J]. Exp Clin Endocrinol Diabetes, 2016, 124(2):77-81. doi:10.1055/s-0042-101165.
[35]	WOODWARD O R M, GRIBBLE F M, REIMANN F, et al. Gut peptide regulation of food intake-evidence for the modulation of hedonic feeding[J]. J Physiol, 2022, 600(5):1053-1078. doi:10.1113/JP280581.
[36]	ADRIAENSSENS A E, BIGGS E K, DARWISH T, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake[J]. Cell Metab, 2019, 30(5):987-996.e6. doi:10.1016/j.cmet.2019.07.013.
[37]	FU Y, KANEKO K, LIN H Y, et al. Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus[J]. Endocrinology, 2020, 161(9):bqaa102. doi:10.1210/endocr/bqaa102.
[38]	LISKIEWICZ A, KHALIL A, LISKIEWICZ D, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice[J]. Nat Metab, 2023, 5(12):2075-2085. doi:10.1038/s42255-023-00931-7.
[39]	CANTACORPS L, COULL B M, FALCK J, et al. Gut-derived peptide hormone receptor expression in the developing mouse hypothalamus[J]. PLoS One, 2023, 18(8):e0290043. doi:10.1371/journal.pone.0290043
[40]	MOFFETT R C, NAUGHTON V. Emerging role of GIP and related gut hormones in fertility and PCOS[J]. Peptides, 2020,125:170233. doi:10.1016/j.peptides.2019.170233.